Publications
The following publications, posters and citations are provided for investors and should not be construed as marketing the use of any Amarin products or product candidates. Copyright to certain documents referenced below are held by their publishers. Where possible, a link is provided to the publisher of the documents. Note that AMR101 is the clinical name for Vascepa® (icosapent ethyl). For more information about Vascepa® (icosapent ethyl) visit www.vascepa.com.
|
Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study) American Journal of Cardiology - 23 July 2012 (10.1016/j.amjcard.2012.05.031)
|
||
|
Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, Placebo-controlled, Randomized, double-blind, 12-week study with an open-label Extension [MARINE] Trial) American Journal of Cardiology 2011; 108:682–690.
|
||
|
Icosapent Ethyl,
a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating
Markers of Inflammation from the MARINE and ANCHOR Studies American Journal of Cardiovascular Drugs - 2013; Jan 17. Epub ahead of print
|
||
|
Effects of Eicosapentaenoic Acid and Docosahexaenoic Acid on Low-density Lipoprotein
Cholesterol and Other Lipids: A Review Journal of Clinical Lipidology - Volume 6, Issue 1, January 2012, Pages 5–18
|
||
|
Icosapent Ethyl, A Pure EPA Omega-3 Fatty Acid: Effects on Lipoprotein Particle
Concentration and Size in Patients With Very High Triglyceride Levels (The MARINE Study) Journal of Clinical Lipidology - Volume 6, Issue 6, November–December 2012, Pages 565–572
|
This page was last updated on February 4, 2013.

